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Studies with mAbs have confirmed the earlier observation (1) that Mycobacte-
rium bovis (Bacillus Calmette-Guerin [BCG]' strain),M . tuberculosis, andM. leprae
share a number of immunoreactive molecules . Murine mAbs raised againstM .
leprae react with carbohydrate and protein antigens common to both mycobac-
teria, as well as apparently M . leprae-specific antigens (2-6) . Recently (7), the
DNA encoding five peptide antigens ofM . leprae has been isolated using a panel
of mAbs in the Xgt 11 expression system, and two of these proteins, with M r
65,000 and 28,000, were shown to possess epitopes common toM . leprae andM .
bovis. Recently (5), we described another mAb, L7, reacting with a 70 kD protein
in crudeM . leprae sonicate that is more abundant inM . bovis and M, tuberculosis
preparations .
The role of the mAb-defined determinants in the human B cell response has
been examined (8) by using leprosy sera in mAb inhibition assays . For example,
we showed (5) that the inhibitory titer was higher for antibodies directed against
cell wall-associated carbohydrate molecules than for those recognizing proteins
ofM, 18,000 and 70,000 . However, protection against mycobacteria is mediated
by T cell responses (9), and purified homogeneous antigens are therefore
required for cellular studies to elucidate the molecular basis of protective
immunity . These antigens may be derivedthrough recombinantDNA technology
by purification of peptides from a suitable expression vector such as Escherichia
coli (10), or by the preparation of synthetic peptides predicted on the basis of the
DNA sequence of individual genes . The alternative approach adopted here is to
usemAb solid-phase affinity chromatography to separate the native antigen from
a soluble preparation of the mycobacteria . The antigen selected was the p70
crossreactive protein recognized by L7 . In view of the limitedsupply ofarmadillo-
derivedM. leprae, the cultivatable mycobacteria M . bovis served as the antigen
source . After purification on an L7 affinity column, the p70 antigen was found
to react with sera from lepromatous leprosy patients, to stimulate peripheral
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blood mononuclear cells (PBMC) from mantoux-positive individuals with release
of I FN--y and to elicit a cutaneous delayed-type hypersensitivity (DTH) reaction .
Materials and Methods
Antigens.
￿
M. bovis (BCG) was obtained as freeze-dried whole bacilli from the Common-
wealth Serum Laboratories (Melbourne, Australia) and M. leprae (preparation CD45) was
kindly provided by Dr. R. J . W. Rees as part of the immunology of Leprosy (IMMLEP)
program. Sonicates of both organisms were prepared as described (5) previously . PPD
was obtained from the Statens Seruminstitut (Copenhagen, Denmark).
Antibodies.
￿
1.7, an IgGI mAb, was derived from a fusion of P3-NSl-Ag4-1 myeloma
cells with spleen cells from BALB/c/J mice immunized with M. leprae sonicate (5). The
antibody was purified from ascites fluid by ammonium sulfate precipitation and protein
A-Sepharose chromatography (11). The human serum pools used were from 10 Nepali
patients with untreated lepromatous and borderline lepromatous leprosy, and from 10
untreated smear-positive patients with pulmonary tuberculosis. Control sera were obtained
from a mantoux-negative healthy Caucasian resident in Sydney .
mAb Affinity Chromatography.
￿
1.7 was coupled to cyanogen bromide-activated Sepha-
rose 4 B (Pharmacia Fine Chemicals, Uppsala, Sweden) at a ratio of 5 mg of antibody to
1 ml gel in 0 .25 M sodium bicarbonate buffer (pH 9.0) containing 0.5 M sodium chloride
for 2 h at room temperature . The gel was then reacted with I M ethanolamine for 2 h at
room temperature before washing alternately with 0.1 M sodium acetate (pH 4.0)
containing sodium chloride (0.5 M) and coupling buffer for four cycles. The washed gel
was then stored in 0 .15 M PBS, pH 7.2, containing 0 .1% sodium azide at 4°C. Normal
mouse (BALB/c/J) Ig purified by protein A-Sepharose chromatography was coupled to
Sepharose 4 B in the same way.
M. bovis sonicate (23 .5 ml, 5 mg/ml) was first passed through a normal mouse Ig-
Sepharose 4 B column and recirculated for 1 h at a flow rate of 2 ml/min. Subsequently,
unbound material was recirculated through a L7 Sepharose 4 B column for 2 h at the
same flow rate. This column was then washed extensively with PBS containing 0.65 M
sodium chloride until a stable baseline was obtained. The bound fraction was eluted with
0 .05 M diethylamine, pH 11 .5, (BDH Chemicals, Poole, England), pooled and dialyzed
against 0.015 M PBS before lyophilization. The lyophilized material was redissolved in
one-tenth of its original volume of sterile water, and the protein concentration was
measured with Folin's reagent (12). The solution was filtered through a 0 .22 Am filter
(Millipore, Bedford, MA) before in vitro or in vivo use.
SDS-PAGE, and Immunoblotting.
￿
The eluted and unbound material, and the original
M. bovis sonicate (10 lAg protein per track) were subjected to 6-20% gradient SDS-PAGE
(13). The protein bands were stained with Coomassie blue (R250 ; Biorad Laboratories,
Richmond, CA) or transferred to nitrocellulose paper (Biorad Laboratories) for immu-
noblotting with L7 as described previously (5). The second antibody used was "'I-labelled
sheep anti-mouse Ig, and the nitrocellulose paper strips were developed by autoradi-
ographic exposure to Kodak XRP-I film (Kodak, Melbourne, Australia) at -70°C. The
' z'1-labelled p70 antigen was also analyzed by one- and two-dimensional PAGE before
and after immunoprecipitation with test sera (see below). Two-dimensional analysis
involved separation in the first dimension by IEF in 7.5% polyacrylamide containing 7.6%
pharmalyte, pH range 4-6 .5 (Pharmacia Fine Chemicals), 2% NP-40, and 4.5 M urea.
This was followed by electrophoresis in the second dimension using 6-20% SDS-PAGE
(14). The gels were stained with Coomassie blue and dried onto filter paper before
development by autoradiography for 24-48 h. The molecular weight markers ranged
from 93,000 to 14,400 (Pharmacia Fine Chemicals) .
Immunoprecipitation.
￿
The eluate from the L7 column containing the p70 antigen (500
Ag/ml, 100 Al) and M. leprae or M. bovis (BCG) sonicate (I mg/ml, 100 Al) were
radiolabelled with 125'1 (Amersham Corp., Buckinghamshire, United Kingdom) by the
chloramine T method (15). The radiolabelled antigen was immunoprecipitated with the
test sera as described by Brown and coworkers (16). Briefly, 4 X 106 cpm of 115I-p70 orBRITTON ET AL.
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"5I-labeled M. bovis (BCG) sonicate in 200 al 0.2% NP-40/PBS were incubated with 10
MI serum for 2 h on ice in a microfuge tube. Staphylococcus aureus, Cowan strain A (Staph.
A; heat-killed, formalin fixed; 10% in PBS; Commonwealth Serum Laboratories, Mel-
bourne, Australia) was added in 500 ul with agitation before incubation on ice for 30
min. Theantigen-antibody Staph. A complex was washed vigorously three timeswith NP-
40/PBS. The antigen was then released by incubation with electrophoresissample buffer
containing 4% SDS, 4% 2-ME, 20% sucrose in 0.05 M Tris-NCI, pH 6.8 for SDS-PAGE,
or with 2% SDS, 2% NP-40, 9.5 M urea for IEF. After centrifugation, a 5 ul sample of
the supernatant was counted before electrophoresis.
ELISA with p70 Antigen.
￿
The p70 fraction was diluted in PBS to concentrations of
100-0.01 ug/ml, andthewellsofapolystyrene microtiter tray (Linbro; Flow Laboratories,
Edinburgh, United Kingdom) were coated with 50 At of each dilution by incubation for
2 h at 37°C. The wells were then blocked with 3% BSA (Miles Laboratories, Naperville,
IL) in PBS/azide for I h. Aliquots of pooled leprosy sera, tuberculosis sera, and control
sera (50 ;At) were added to triplicate wells of each antigen concentration at a dilution of
1:300 in 0.1% BSA/PBS/Tween 20 for 1 h. After extensive washing, the wells were
pulsed with goat anti-human IgG conjugated with alkaline phosphatase (Sigma Chemical
Co., St. Louis, MO) diluted 1:1,000 in 0.1 % BSA/PBS/Tween 20 (50 At) and incubation
continuedfora furtherhour. Colorwasdeveloped by theaddition oftheenzyme substrate,
nitrophenyl phosphate (Sigma Chemical Co.), and the ODs were read at 30 and 60 min
in a Titertek Multiscan (Flow Laboratories) at 405 nm.
Antigen Inhibition Assay.
￿
Doubling dilutions of the purified p70 and the original M.
bovissonicate were addedto BSA-blockedround-bottom wells in a microtiter tray together
with an equal volume of fresh L7 hybridoma culture supernatant for incubation at 37°C
for I h. 50 ul of each dilution was transferred in triplicate to microtiter tray wells which
had been coated with M. bovis sonicate (50 ug/ml) and then with 3% BSA. This was
followed by alkaline phosphatase-conjugated sheepanti-mouse Ig (New EnglandNuclear,
Boston, MA) and enzyme substrate.The mean OD ofwells incubated with BSA alonewas
subtracted from that of each test well. Since maximum binding occurred with L7 diluted
1 :2, thepercentage inhibition ofmaximum bindingachieved at each antigen concentration
could be calculated.
Human T Cell Reactivity.
￿
PBMC were separated from heparinized venous blood of
subjects by centrifugation over Ficoll/Hypaque (17). After washing with RPMI 1640
(Flow Laboratories) containing 10 mM sodium bicarbonate and 25 mM Hepes, the cells
were adjusted to a concentration of 106 cells/ml with RPMI containing 20% heat-
inactivated (A-) human serum, penicillin (50 mg/liter) and streptomycin (100 mg/liter).
200 ul aliquots containing 2 X 105 cells were added to the wells of flat-bottom microtiter
trays (Linbro; Flow Laboratories) followed by various concentrations of antigens in 25 ul
of RPMI. In the case of p70 and M. bovis, the final concentrations were 10, 3, 1.0, 0.3,
and 0.1 jug/ml, whereas for PPD they were 10, 1.0, and 0.1 ug/ml. After 5 d incubation
at 37°C in 5% C02, each well was pulsed with 1.0 uCi of ['H]thymidine (Amersham
Corp.), andthecells were harvested 16 h later. [sH]thymidineincorporation wasmeasured
in dpm by liquid scintillation spectroscopy (1218 Rackbeta; LKB Instruments, Gaithers-
burg, MD). Before addition of [5H]thymidine, 100 ul of supernatant was removed from
the triplicate wells and replaced with 100 ul of fresh medium. The 100 ul samples were
then pooled and stored at -20°C for subsequent measurement of IFN-y activity (18).
IFN-y activity was measured by a cytopathic effect-inhibition assay using the method
of Ho and Enders (18). HEp-2 cells were grown to confluence in microtiter trays. IFN
standards and samples were diluted and incubated with the cells for 24 h at 37'C. The
rnatants were then removed and replaced with 4 X 10' PFU/well of Semliki Forest
us. After a further 48 h incubation at 37°C, the cells were fixed and stained with
neutralred. Endpoint dilutionswere read at 50%protection ofcytopathic effect inhibition .
The human reference IFN-y was supplied by the National Institute of Allergy and
Infectious Diseases, National Institutes of Health (Bethesda, MD).
For DTH skin testing, the p70 antigen was adjusted to a final concentration of 1 ug/ml
in sterile PBS. 100 ul was injected intradermally on the volaraspect of the forearm, and698
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FIGURE 1 . SDS-PAGE fractionation of L7 column-purified antigen from M. bovis (BCG)
sonicate . A . Gel stained with coomassie blue (20 kg/track) . B . Immunoblot (10 Ag/track)
probed with L7 (10 ug/ml) and sheep anti-mouse Ig labelled with "'I, and autoradiograph-
developed for 2 d at -70° . Lanes a and d, original sonicate ; b and e, pH 11 .5 eluate ; c andf,
unbound fractions eluted with PBS .
the horizontal and vertical diameters were measured in millimeters 48 and 72 h later .
The PBS diluent was also injected intradermally for comparison .
Subjects .
￿
Ethical approval for the use of the purified p70 antigen was obtained from
the University of Sydney Human Studies Ethics Committee . The subjects consisted of
healthy volunteers who were skin tested with tuberculin PPD (100 U/ml ; Commonwealth
Serum Laboratories). 12 had received BCG vaccinations and were PPD+ , 7 were naturally
PPD+ , and 8 were PPD- without prior vaccination or known contact with tuberculosis .
AminoAcid Sequencing .
￿
The p70 antigen (^,25 jug) was analyzed on a Model 890A gas-
phase sequencer (Applied Biosystems, Inc ., Foster City, CA) . It was first dissolved in 98%
formic acid (20 jul) and loaded into a glass fiber disc that had been pretreated with
trifluoroacetic acid . The phenylthiohydantoins (PTHs) were identified by HPLC (19) .
Results
Separation ofp70 Antigen by Solid-phase Affinity Chromatography.
￿
From 117 .5
mg ofM . bovis sonicate applied to the L7-Sepharose 4 B column, 1 .6 mg (1 .3%)
were eluted with alkaline (pH 11 .5) buffer . Staining of SDS-PAGE-fractionated
samples (10 ug) revealed a marked increase in the density and size of the 70 kD
band in the pH 11 .5 eluate compared to the faint band seen in tracks of the
original sonicate, while the unbound material (PBS fraction) was depleted of this
band (Fig . I A) . There was a faint second band of M, 68,000 beneath the major
band, and this pattern resembled the doublet of L7-reactive bands obtained
previously (5) on immunoblots of crude M. leprae andM . bovis sonicates . In
addition, when 20 Ag of pH 11 .5 eluate was applied, faint bands were present
with M,. 60,000 and 32,000 . The increased concentration of the L7 reactive
protein in the pH 11 .5 eluate was confirmed by immunoblotting, and faint
reactivity was present in the region ofMr 60,000 and 32,000 (Fig . 1 B), consistent
with these being fragments of the p70 antigen . Once again the PBS fraction
contained no demonstrable p70 antigen . The reactions with the original sonicate
were relatively weak, which was consistent with the results obtained in earlier
experiments (5) comparing various anti-M. leprae mAbs . Examination of the pH
11 .5 eluate from the normal mouse Ig column revealed faint protein bands ofN
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FIGURE 2. Antigen-inhibition ELISA in which antigen solutions were incubated with L7
supernatant before L7 wasused in an ELISA with M. bovis(BCG) sonicate. Inhibiting antigens
were M. bovis sonicate (0);and p70antigen purified from L7 column (O).
Mr 55,000 and 27,000, but no immunoreactive p70 on immunoblotting with L7
(data not shown).
Reactivity of p70 with the L7 mAb.
￿
Enrichment of p70 in the column eluate
was confirmed in the antigen-inhibition ELISA. Using crude sonicates of M.
leprae or M . bovis, high protein concentrations (500-1,000 'ag/ml) were required
to inhibit the binding of L7 to antigen-coated wells. With the pH 11 .5 fraction,
the inhibition curve was shifted to the right (Fig. 2) and the concentration causing
50% inhibition of binding of L7 to M. bovis was 20 tag/ml, compared to 750
Ag/ml for the whole sonicate.
Reactivity of p70 with Leprosy and Tuberculosis Sera.
￿
Incubation of I25I-M.
leprae sonicate with the pool of leprosy sera had indicated that the Mr 70,000
band was one of 13 bands immunoprecipitated by human immune sera. L7
precipitated a similar band from M. leprae and M. bovis sonicate in a solid-phase
immunoprecipitation assay (data not shown). Therefore, we examined the reac-
tivity of p70 with antisera from patients with leprosy and tuberculosis. In the
direct ELISA, human leprosy sera reacted with the p70 fraction diluted to 0.01
jug/ml, whereas 1 Ag/ml was required for significant binding to tuberculosis sera.
At each dilution, the leprosy serum pool was more reactive than the tuberculosis
sera pool with the p70 antigen (Fig. 3).
Thep70-containing fraction was radiolabelled with '25I. Autoradiography after
SDS-PAGE revealed a dense band at M,- 70,000 with faint bands at 67,000 and
35,000 . Two-dimensional electrophoresis showed that the radiolabelled p70 had700
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FIGURE 3 . Direct ELISA using p70 purified from L7 column . The serum pools were
incubated with p70 at different concentrations and the ELISA developed. The serum pools
were derived from patients with lepromatous leprosy (0), tuberculosis sera (O), or normal
mantoux-negative controls (A) .
FIGURE 4.
￿
Two-dimensional electrophoresis with separation in the horizontal dimension by
IEF, and in the vertical dimension by mol wt with SDS-PAGE . IEF markers are, from the
cathode end, pH 5 .85, 5.20, 4.55, and 4.15 . M, markers (X 10-s) are on the left side . A. 105
cpm of '251-labelled pH 11 .5 eluate from L7 column . B. The same antigenic material immu-
noprecipitated by lepromatous leprosy sera (see text) .
a pI of 5.35 (Fig . 4A) . After incubation with the leprosy serum pool, 17,778 cpm
per 5 A1 of the 1251-p70 (5.3%) were subsequently eluted from the Staph . A
complex and compared to 6,019 cpm per 5 Al (1 .8%) and 5,484 cpm per 5 Al
(1 .6%) after incubation with tuberculosis and control sera, respectively . Two-
dimensional electrophoresis of the eluted material confirmed that p70 had beenBRITTON ET AL .
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FIGURE 5 .
￿
Two-dimensional electrophoresis as in Fig. 5, except that theantigen was (A) 10 5
cpm of 'ssI-M . bovis (BCG) sonicate ; (B) "'I-M. bovis BCG sonicate immunoprecipitated by
lepromatous leprosy sera .
precipitated by the leprosy sera (Fig . 4B) . In addition, a faint M, 35,000 band
was precipitated by the immune sera .
Comparison of 1251-p70 with I25I-M. bovis sonicate examined under similar
conditions showed the enrichment of p70 by affinity chromatography (Fig . 5) .
>50 bands were visible in M. bovis (BCG) sonicate, and 20 of these were
precipitated by leprosy sera . ' 25 I-p70 migrated to the same position as one of
these bands (Fig . 5A). A similar protein was identified by immunoprecipitation
of 1251_M . leprae sonicate with either L7 or leprosy sera (data not shown) .
In Vitro T Cell Reactivity.
￿
The presence of T cell-reactive epitopes on the
purified p70 antigen was tested in vitro by proliferation and IFN-y release, and
in vivo by DTH. Initially, the cellular reactivity of the purified p70 antigen was
compared with the originalM . bovis sonicate in a proliferative assay over a dose
range of 0.1-10 gg/ml (Fig. 6) . Among the eight controls with no exposure to
tuberculosis and no skin test reactivity to PPD, only one had a mild proliferative
response to p70 and M . bovis . By contrast, marked proliferation to the p70
antigen and M . bovis sonicate at concentration 10-0.3 ug/ml was observed in
both BCG-vaccinated subjects and those with natural immunity toM . tuberculosis,
the highest response occurring in the latter group . In a few individuals, the
response to p70 andM. bovis at the same concentration was comparable, but in
the majority of cases the p70 response was 50-70% of that to whole sonicate
(Table I) .
The release of IFN-y into the culture supernatant during the proliferative
response to p70 andM. bovis was measured in some subjects (Table II) . The
lymphokine was only detected in supernatants derived from cultures in which
the cells had responded to p70 orM . bovis . However, the higher concentration
of 10 yg/ml was required for detectable IFN-y to be present in cultures from all
the skin test-positive individuals (Table 1I) .
DTH Reactivity ofp70.
￿
The in vivo response to p70 was examined in the same
three groups of subjects . Initial observations with p70 at concentrations of 1.0-702
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Proliferative responses of PBM to p70 antigen. Individual points represent the
mean ± SEM of the Odpm at that antigen concentration for the members of each group.
Naturally mantoux-positive (A); BCC-vaccinated (/); Mantoux-negative controls (0).
DTH skin test
(mean diame-
tert SEM;
Group
￿
Number
￿
mm) for M.
TABLE I
TCell Responses to M. Bovis Sonicate and Purified p70 Antigens
Lymphocyte proliferation ([sH]thymidine
incorporation; 0 dpm mean ± SEM) for
innoculum of:
Groups were; 1, naive recipients; 2, BCC-vaccinated recipients; 3, recipients
with natural reactivity to PPD.
* Significantly different from naiverecipients at p < 0.01.
$ Significantly different from naiverecipients at p < 0.005 .
bovisp70
(1 Ag/ml)
innoculum
M. bovis p70
(1 tag/ml)
M. bovis
(1 ug/ml)
1 8 0 1,952 ± 536 1,899 ± 575
2 12 8.8 ± 1.4 24,545 ± 8,519* 40,422 ± 10,806$
3 7 12.2 ± 2.6 42,187 ± 12,812$ 84,714 ± 29,398$BRITTON ET AL.
TABLE 11
In Vitro IFN-,y Production to p70 and M. Bovis
Measured by CPE-inhibition assay. Groups as in Table 1.
*Number of individuals responding is given in parentheses.
IFN--y (IU/ml; mean ± SEM) for innocula of:
Group
￿
Number
￿
M. bovis p70
￿
M. bovis
10 kg/ml
￿
1 'Ug/ml
￿
10 ug/ml
￿
1 rig/ml
1
￿
4
￿
0
￿
0
￿
0
￿
0
2
￿
7
￿
983 ± 309(7)*
￿
103 ± 90
￿
(2)
￿
297 ± 65
￿
(7)
￿
46 ± 45
￿
(1)
3
￿
6
￿
1,066 ± 135 (6)
￿
386 ± 205 (4)
￿
693 ± 212 (6)
￿
533 ± 257 (4)
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0.01 jug/ml indicated that, although some strongly reactive subjects responded
to p70 at concentrations of 0.01 Mg/ml, other PPD+ individuals only did so at 1
,ug/ml . Therefore, 100 A,1 of p70, 1 gg/ml, was selected as the test dose for
intradermal injection into the 27 subjects. There were no responses to the PBS
diluent. Mantoux-negative individuals had no skin test reactivity to p70, including
the subject with a mild proliferative response to p70 (Table 1). A number of the
responsive subjects (4 of 19) displayed an initial flare reaction, which subsided
after 12 h, but the cutaneous oedema reaction peaked at 48-72 h and then
subsided. The results at 48 h indicated that BCG-vaccinated subjects reacted to
a lesser extent than those with natural reactivity to PPD. When the relationship
between skin test reactivity and proliferative response at 1 Ag/ml was examined,
a moderately significant correlation was observed between the two responses
(Spearman rank coefficient, 0.708).
Partial Amino Acid Sequence.
￿
The N-terminal sequence of the p70 antigen was
analyzed by a gas-phase sequenator; the first 15 amino acids are: Ala-Arg-Ala-
Val-Gly-lie-Asp-Leu-Gly-Thr-Asp-Asn-Ser-Val-Val. The chromatograms showed
a persistent background of PTH-amino acids (particularly PTH-aspartic acid),
but the major peak (except for cycle 2) was always at least double the height of
background peaks. While PTH-arginine was not the largest peak in cycle 2,
relative to cycle 1 it increased the most, and because this derivative is less easily
extracted from the sequencer than others, residue 2 was assigned as arginine.
Discussion
Mycobacteria such as M. leprae, M. bovis, and M. tuberculosis present multiple
antigens to the infected host (20). These are derived from the complex cell wall
surrounding the bacterium with its matrix of polysaccharides and peptides linked
to a peptidoglycan backbone, or are released from the cytoplasm (21). Recent
studies (6, 22) with mAbs raised against these three mycobacteria have led to the
identification of a number of glycolipid, carbohydrate, and protein antigens.
Among these mAbs was L7, which recognized an antigen ofM, 70,000 (p70), its
distribution being restricted to M. leprae, M. bovis, M. tuberculosis, and M.
scrofulaceum within the panel of 14 mycobacteria tested (5). The antigen was a
protein, as indicated by its sensitivity to subtilisin and trypsin and its resistance
to periodate oxidation, but it was not associated with the mycobacterial cell wall .
p70 is distinct from the 60-65,000 complex identified by Gillis and coworkers704
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(23) and ourselves as a cell wall-associated peptide. The excellent separation of
p70 achieved with L7 from either M. bovis or M. leprae sonicates in a solid-phase
imrnunoprecipitation assay suggested that it would be a suitable antibody for
affinity chromatography. This was substantiated when the material eluted from
the L7-Sepharose column was shown to consist predominantly ofthe p70 antigen
(Fig. 1). Two-dimensional electrophoresis ofwhole BCG sonicate and p70showed
the relative homogeneity of the purified antigen. The minor M,. 32,000 and
60,000 bands were reactive with L7 and were thought to reflect the effect of
proteolytic enzymes on p70. Treatment of crude sonicate with trypsin before
immunoblotting with L7 showed that p70 could been cleaved into L7-reactive
fragments (data not shown). The antigenic activity of the pH 11.5 fraction from
the L7-Sepharose column was therefore considered to reside in the dominant
p70 protein.
The enhanced reactivity ofthe pH 11.5 fraction in the antigen-inhibition assay
(Fig. 2) confirmed the concentration of p70 observed in immunoblots. The
antigen was shown to react directly with leprosy sera, which in conjunction with
the results from the monoclonal inhibition studies indicated that the L7 deter-
minant was recognized by human B cells (Fig. 3). Interestingly, p70 was readily
detected by imrnunoprecipitation with human sera, whereas it was not well seen
in immunoblots (5, 25, 26). These findings illustrate the different sensitivity of
the two techniques . Determinants on other proteins of M. leprae, including the
M,. 18,000, 36,000, and 65,000 antigens have been shown previously (5, 8) to be
human B cell immunogens in mAb inhibition assays. Recently (27) this has been
validated in the case of the 65,000 antigen with direct binding studies using the
homologous protein purified from M. gordonae.
The protective response to mycobacteria is mediated by activated T cells and
their products rather than antibodies (9). Evidence of a role for the p70 antigen
in cellular immune responses was obtained from both in vitro and in vivo studies.
When PBM from mantoux-positive donors were cultured in the presence ofp70
or M. bovis sonicate, a dose-dependent proliferative response occurred to both
antigen preparations, with release of IFN-y (Fig. 6, and Tables I and I1). The
degree of proliferation to p70 was 50-100% of that to the original sonicate,
indicating that p70 is likely to be a significant T cell immunogen. Although it
will be necessary to carry out limiting-dilution analysis to prove this conclusively,
the DTH reactivity of p70 strongly supports its importance in T cell responses
to M. bovis, and probably to M. tuberculosis and M. leprae as well. Evidence in
favor of this comes from the observation that human T cell clones with cross-
reactivity for M. bovis and M. leprae underwent substantial proliferation in the
presence of purified p70 (data not shown).
The cellular activity of p70 from M. bovis in man suggests that it has the
potential to stimulate protection against infection with M. bovis, M. tuberculosis,
and possibly M. leprae. It will be possible to test this in the case ofM. tuberculosis
by using a murine model of infection in which protection is assayed in mice
immunized with p70 or M. bovis sonicate . With M. leprae infection, p70 purified
from M. bovis may mimic the protection achieved with whole M. bovis in the
mouse footpad assay (28). However, it. will be more relevant to test p70 derived
from M. leprae itself in this system, when it becomes available, possibly throughBRITTON ET AL.
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recombinant DNA technology (vide infra) . In the interim, p70 purified from M.
bovis is being tested for its ability to elicit DTH in subjects with tuberculosis and
in leprosy patients across the clinical spectrum .
Other well-characterized mycobacterial antigens have been recently shown to
express T cell reactive epitopes. For example, others (29, 30) have isolated
human T cell clones responding to an antigenic fraction purified from M.
tuberculosis with mAb TB 68. This antigen was identified as a molecule of Mr
120,000, which after SDS denaturation resolved into four bands, each of which
wasdistinct from the p70 antigen described here. Usingadifferent mAb directed
against M. bovis (BCG), Minden and coworkers (31) purified a 10,000 M, protein
and showed that it had DTH reactivity in sensitised guinea pigs. Recently,
Mustafa and coworkers (32) examined the T cell reactivity of five M. leprae
peptides expressed in E. coli with the XgtI l system . They sought to circumvent
the need to purify individual antigens from the expression vector by using E. coli
Iysates, which they tested against a panel of T cell clones derived from subjects
vaccinated with M. leprae. M. leprae-specific T cell clones were stimulated only
by E .. coli lysates containing the epitope recognized by mAb (L7.15), shown
previously (5) to identify an M. leprae-specific determinant on an M, 18,000
protein. This finding did not exclude the possibility that the other four peptide
antigens ofM, 65,000, 36,000, 28,000, and 12,000 werealso T cell immunogens,
since only a relatively small number of T cell clones were tested. In fact, using
proteins purified with mAb affinity chromatography or HPLC, both the M,.
36,000 and 12,000 antigens were shown (33) to stimulate human T cell clones
obtained from a patient with tuberculoid leprosy. Although the 36,000 protein
had been defined with an M. leprae-specific mAb, only one ofthe four responsive
T cell clones was M. leprae-specific, indicating that common mycobacterial
determinants were also present on the 36,000 protein.
A recent IMMTUB (Immunology of Tuberculosis) workshop (34) compared
the reactivity of anti-M. tuberculosis mAbs, and sought to identify DNA clones
ofM. tuberculosis expressing mAb-defined epitopes using the same bacteriophage
vector, Xgt11. Among the 31 mAbs tested, one (51A) reacted with a band of
71,000 M,. and showed a limited pattern of crossreactivity. 51A identified a
48,000 band in M. leprae immunoblots, suggesting that it recognized a different
epitope from that defined by L7 (O. Closs, personal communication). DNA
clones ofM. tuberculosis encoding the epitope defined by 51A in M. tuberculosis
sonicate immunoblots have been isolated (34). It remains to be established
whether L7 recognizes the protein expressed by these clones or whether they
crosshybridize with the two DNA clones recently isolated from the M. leprae
genomic library with L7 byJ. D. Watson (Auckland Medical School, Auckland,
New Zealand; personal communication). If the proteins are related, purification
ofthe E. coli-expressed 71,000 M. tuberculosis protein in whole or part will allow
comparison between the cellular reactivity of the native p70 protein and the E.
coli expression product. Ultimately, such studies will elucidate the role of the
p70 antigen in stimulating protective responses to M. leprae, M. tuberculosis, or
both bacteria in infected individuals, and will determine whether it might be a
suitable candidate for inclusion in a polyspecific vaccine.706
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Summary
The protein antigens from Mycobacterium bovis (BCG), M. tuberculosis, and M.
leprae share a number of common determinants . We have used a murine mAb
(L7) recognizing such a determinant on a protein of Mr 70,000 to purify this
antigen from M. bovis sonicate by affinity chromatography. Enrichment of the
protein in column eluates was confirmed by immunoblotting and in antigen
inhibition assays. After radiolabelling with
1251, the protein could be immuno-
precipitated with human lepromatous leprosy sera. Stimulation of peripheral
blood mononuclear cells from BCG-vaccinated and naturally mantoux-positive
individuals induced proliferation and IFN-y secretion, while intradermal injec-
tion of purified antigen into the same subjects resulted in a delayed-type hyper-
sensitivity reaction . Thus, the 70,000 molecule carried epitopes capable of
reacting with B cells, and eliciting a potentially protective T cell response . The
first 15 N-terminal residues were sequenced using a gas-phase sequenator .
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